These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20509268)

  • 21. European Commission approves Atripla.
    AIDS Patient Care STDS; 2008 Jan; 22(1):87-8. PubMed ID: 18453042
    [No Abstract]   [Full Text] [Related]  

  • 22. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 23. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
    Elion R; Berger D; Richmond G; Sension M; Dejesus E; Cimoch P; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2010; 11(3):170-3. PubMed ID: 20736153
    [No Abstract]   [Full Text] [Related]  

  • 24. Triple combinations regimens for HIV.
    Lancet Infect Dis; 2003 Nov; 3(11):682. PubMed ID: 14603888
    [No Abstract]   [Full Text] [Related]  

  • 25. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugs of tomorrow.
    Posit Aware; 1998; 9(3):27-31. PubMed ID: 11365484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).
    Zapor MJ; Cozza KL; Wynn GH; Wortmann GW; Armstrong SC
    Psychosomatics; 2004; 45(6):524-35. PubMed ID: 15546830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical update: new drugs for HIV/AIDS.
    Gracia Jones S; Baggett TH
    Medsurg Nurs; 1999 Apr; 8(2):108-12. PubMed ID: 10410008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
    [No Abstract]   [Full Text] [Related]  

  • 31. [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92. PubMed ID: 15373069
    [No Abstract]   [Full Text] [Related]  

  • 32. Releasing the true power of protease inhibitors.
    Raffi F
    Int J STD AIDS; 2003 Oct; 14 Suppl 1():29-33. PubMed ID: 14617401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 34. Raltegravir as effective as efavirenz in 144-week data.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
    [No Abstract]   [Full Text] [Related]  

  • 35. Three new drugs for HIV infection.
    Med Lett Drugs Ther; 1998 Dec; 40(1041):114-6. PubMed ID: 9854567
    [No Abstract]   [Full Text] [Related]  

  • 36. Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
    AIDS Treat News; 1997 Dec; (No 284):4. PubMed ID: 11364914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drugs on the horizon.
    Proj Inf Perspect; 1998 Apr; (24):10-3. PubMed ID: 11365712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA notifications. FDA approves generic combination of efavirenz, lamivudine & tenofovir.
    AIDS Alert; 2009 Nov; 24(11):130. PubMed ID: 19960612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.